drugset / Trial / NCT00563836

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

NCT00563836 ↗

Phase 2 Completed 41 enrolled Neovii Biotech
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Primary evaluation of the safety, tolerability and feasibility regarding specific postoperative complications of an adjuvant treatment with catumaxomab administered after tumor resection.

Timeline

Start
2007-11
Primary completion
2008-09
Completion
2010-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Catumaxomab Monoclonal antibody 150 ug Other